Literature DB >> 6313358

In vitro activity of HR 810, a new broad-spectrum cephalosporin.

K Machka, I Braveny.   

Abstract

HR 810, 3-[(2,3-cyclopenteno-1-pyridinium)methyl]-7-[2-syn-methoximino-2-(2-aminothiazole-4-yl)-acetamido] ceph-3-em-4-carboxylate, is a new semisynthetic cephalosporin derivative. The in vitro activity of HR 810 was compared with that of cefotaxime, ceftazidime, piperacillin and gentamicin using 368 strains of gram-negative and gram-positive bacteria. HR 810 was highly active against Enterobacteriaceae, being the most active of the cephalosporins against Enterobacter, Serratia and Citrobacter spp.; the MICs ranged from much less than 0.06 to 8 mg/l. The activity of HR 810 against Pseudomonas aeruginosa and Acinetobacter spp. was almost as good as that of ceftazidime. The new compound was superior to the other cephalosporins against Staphylococcus aureus and inhibited all Streptococcus faecalis strains at a concentration of 16 mg/l.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313358     DOI: 10.1007/bf02019465

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  7 in total

1.  Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810.

Authors:  A Bauernfeind
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

2.  Relation between beta-lactamase production and antimicrobial activity: comparison of the new compound HR 810 with cefotaxime.

Authors:  W Cullmann; W Opferkuch; M Stieglitz
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

3.  HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase.

Authors:  R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

4.  Evaluation of the Micur microdilution systems for antibiotic susceptibility testing of gram-negative and gram-positive bacteria.

Authors:  F Kayser; K Machka; L Wieczorek; D Banauch; W Bablok; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

5.  Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins.

Authors:  A H Seeberg; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

6.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

7.  Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Authors:  R Platt; S L Ehrlich; J Afarian; T F O'Brien; J E Pennington; E H Kass
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

  7 in total
  12 in total

1.  In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627.

Authors:  M Yoshida; S Mitsuhashi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

2.  In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents.

Authors:  R Wise; C Cross; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

3.  Antimicrobial activity of HR810 against 419 strict anaerobic bacteria.

Authors:  R N Jones; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

4.  In vitro activity of HR 810, a new cephalosporin.

Authors:  M A Bertram; D A Bruckner; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

5.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  Anti-pseudomonal activity of HR 810.

Authors:  M O Husson; D Izard; A Bryskier; H Leclerc
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

7.  The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

8.  Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrum.

Authors:  S Kobayashi; S Arai; S Hayashi; K Fujimoto
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.

Authors:  D Paradis; F Vallée; S Allard; C Bisson; N Daviau; C Drapeau; F Auger; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Authors:  R N Jones; C Thornsberry; A L Barry; L Ayers; S Brown; J Daniel; P C Fuchs; T L Gavan; E H Gerlach; J M Matsen
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.